Novartis Vaccines Unit Makes Move Into Crowded CMV Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.
You may also be interested in...
Novartis Unveils Promising Phase II Data For Meningitis B Vaccine
Data show dosing series produces protective immune response in infants.
Phase III Menveo Beats Menactra In Teen Meningitis
Novartis will submit vaccine for U.S. and overseas approval later this year.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.